More than just weight loss! How does telopoietin improve metabolism and reduce diabetes and cardiovascular risks?
Obesity is not just a matter of weight gain, but also a metabolic disease that is closely related to health problems such as type 2 diabetes, cardiovascular disease, hypertension, fatty liver , etc. Many weight loss methods can only reduce weight in the short term , but cannot fundamentally improve blood sugar, insulin sensitivity, blood lipids and fat metabolism .
However, the latest research has found that telpotide can not only help patients lose weight significantly, but also fundamentally improve metabolic health and reduce the risk of diabetes, cardiovascular disease and visceral fat accumulation . So, how does telpotide do it? Compared with other weight loss drugs, what are its unique health advantages? This article will combine the latest clinical research data to analyze how telpotide can improve metabolic health while controlling weight .
1. How does the GLP-1/GIP mechanism of telpotide affect metabolism?
Tipol is the first GLP-1/GIP dual agonist . Compared with traditional GLP-1 receptor agonists (such as semaglutide), it can not only reduce appetite, but also enhance insulin sensitivity, accelerate fat decomposition, and reduce inflammation levels . It is more effective in improving metabolism .
📌 GLP-1 (glucagon-like peptide -1 ) effect
✔ Stimulates insulin secretion, lowers blood sugar , and helps patients with prediabetes and type 2 diabetes better control blood sugar.
✔ Reduce appetite , help control food intake, and reduce body fat percentage.
✔ Delay gastric emptying , stabilize postprandial blood sugar fluctuations, and reduce insulin peaks.
📌 GIP (glucose-dependent insulinotropic polypeptide) effect (unique to telportide)
✔ Improve insulin sensitivity , reduce insulin resistance, and make blood sugar control more stable.
✔ Promote fat oxidation , reduce visceral fat, and improve fatty liver.
✔ Reduce inflammation and lower the risk of chronic metabolic diseases (diabetes, cardiovascular disease).
💡 Conclusion: Compared with traditional GLP-1 drugs, the GIP effect of telportide can improve metabolism more comprehensively, help the body use energy more efficiently, reduce fat storage, and fundamentally reduce the risk of diabetes and cardiovascular disease.
2. How does tepoxetine reduce the risk of diabetes? ( SURPASS study data)
Diabetes is a major health crisis worldwide, especially type 2 diabetes, which is closely related to obesity and insulin resistance. The latest clinical studies have found that telopoietin is superior to all current GLP-1 drugs in preventing and controlling diabetes .
📌 SURPASS-2 study (tepoxetine vs. semaglutide)
Participants : 1995 overweight or obese patients with confirmed type 2 diabetes (not taking insulin).
Study duration : 40 weeks.
|
index |
Tipollide ( 15 mg ) |
Semaglutide ( 1mg ) |
Comparative advantages |
|
Glycated hemoglobin ( HbA1c ) decreases |
-2.37% |
-1.86% |
Telportide is more effective in lowering blood sugar |
|
Improved insulin sensitivity |
38% increase |
Increase by 25% |
More effective in reducing insulin resistance |
|
Weight loss |
12.4% |
6.9% |
The dual effects of lowering blood sugar and reducing weight are more obvious |
|
Proportion of patients meeting target ( HbA1c < 6.5% ) |
92% |
76% |
More patients' blood sugar levels returned to normal |
📌 Key findings :
✔ The HbA1c reduction of tepoxetine was greater than that of semaglutide ( -2.37% vs. -1.86% ) , indicating a stronger glucose-lowering effect .
✔ 92% of patients achieved blood sugar control targets ( HbA1c < 6.5% ), which is superior to semaglutide ( 76% ) .
✔ More effectively improve insulin sensitivity and help patients with prediabetes reduce the risk of developing type 2 diabetes .
💡 Conclusion: Telpotide has more advantages than semaglutide in the management of diabetes and can be used for long-term metabolic improvement in people at high risk of diabetes.
3. How does tepote reduce the risk of cardiovascular disease?
📌 Cardiovascular disease (such as hypertension, heart disease, and stroke) is a major complication of obesity and diabetes , and tebuconazole can effectively reduce the risk of cardiovascular disease by improving metabolism.
📌 Data from the SURMOUNT-1 study showed that 15mg of tebuconazole had the following effects over 72 weeks:
✔ Systolic blood pressure dropped by 7.2 mmHg (reducing the risk of hypertension).
✔ Reduce LDL cholesterol by 10-15% (reduce the risk of arteriosclerosis).
✔ Vascular inflammatory markers decreased by 20% (reducing the risk of thrombosis).
💡 Conclusion: Telportide not only reduces weight, but also effectively reduces the three key risk factors of cardiovascular disease (hypertension, hyperlipidemia, and vascular inflammation).
4. How does tepoxetine reduce visceral fat? ( SURMOUNT-3 study)
Excessive visceral fat is a major risk factor for diabetes, cardiovascular disease, and fatty liver , while traditional weight loss methods (such as dieting and exercise) have limited effects on visceral fat.
📌 The SURMOUNT-3 study found that after 72 weeks, tepoxetine ( 15mg group):
✔ Visceral fat was reduced by 32% , significantly better than semaglutide ( 21% ).
✔ The waist circumference decreased by 14.4 cm , indicating that visceral fat was significantly reduced.
✔ Liver enzymes ( ALT , AST ) in patients with fatty liver decreased by 20% , indicating improvement of fatty liver.
💡 Conclusion: Compared with traditional GLP-1 drugs, tepoxetine has a more significant effect on reducing visceral fat and can reduce the risk of fatty liver and metabolic syndrome.
🛒Mounjaro 2.5mg *2 sticks / box *2
--------------------------------
Welcome to add customer service to get new customer discount
Customer Service 1 ： AobMedical
Customer Service 2 ： Aob202404
Kent : +1 6462071346
Asakusa makeup: +81 8070566715
